Skip to main content
Top
Published in: Systematic Reviews 1/2018

Open Access 01-12-2018 | Protocol

Diagnostic accuracy of molecular methods for detecting markers of antimalarial drug resistance in clinical samples of Plasmodium falciparum: protocol for an update to a systematic review and meta-analysis

Authors: Rebekah Burrow, Thomas R. Fanshawe, Georgina S. Humphreys

Published in: Systematic Reviews | Issue 1/2018

Login to get access

Abstract

Background

Each year, infection with Plasmodium causes millions of clinical cases of malaria and hundreds of thousands of deaths. Resistance to different antimalarial medications continues to develop and spread, threatening effective prophylaxis and treatment. Surveillance of resistance is required to inform health policy and preserve effective antimalarial drugs; molecular methods can be used to surveil likely parasite resistances. However, there is no consensus on the most accurate molecular methods, and large variation exists in practice. The objective of this update to this systematic review is to improve and update identification of the sensitivity and specificity of each molecular method for detecting selected antimalarial drug resistance markers.

Methods

We will include diagnostic accuracy studies that compare at least two of any molecular methods to examine blood samples from patients diagnosed with, or suspected of having malaria, to detect at least one selected marker of antimalarial drug resistance. We will search PubMed, EMBASE, BIOSIS, and Web of Science from 2000 to present. Two reviewers will independently screen all results, extract data, consider applicability, and evaluate the methodological quality of included studies using QUADAS-2. We will carry out a meta-analysis and use statistical methods to compare results from homogenous studies. We will use narrative to synthesise and compare results of heterogeneous studies.

Discussion

This review will help to identify sub-optimal molecular methods for antimalarial marker detection which may be discontinued and identify more sensitive and specific methods which may be adopted. More sensitive and specific detection of drug resistance can be used to improve the breadth and accuracy of surveillance. This would enable the identification of previously undiscovered areas of antimalarial resistances and susceptibilities, improve the precision of estimates of the prevalence of resistances, and improve our ability to detect smaller changes in these patterns. Higher-quality evidence generated by more accurate and detailed surveillance can be used to inform guidelines on the use of antimalarial drugs, leading to better outcomes for more patients.

Systematic review registration

This systematic review protocol was registered with PROSPERO on 22 November 2017 (registration number CRD42017082101).
Appendix
Available only for authorised users
Literature
3.
go back to reference WHO. Guidelines for the treatment of malaria. In: Guidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015. WHO Guidelines Approved by the Guidelines Review Committee. WHO. Guidelines for the treatment of malaria. In: Guidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015. WHO Guidelines Approved by the Guidelines Review Committee.
4.
go back to reference Bousema JT, Gouagna LC, Meutstege AM, Okech BE, Akim NI, Githure JI, Beier JC, Sauerwein RW. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Tropical Med Int Health. 2003;8:427–30.CrossRef Bousema JT, Gouagna LC, Meutstege AM, Okech BE, Akim NI, Githure JI, Beier JC, Sauerwein RW. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Tropical Med Int Health. 2003;8:427–30.CrossRef
5.
go back to reference Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000;44:2100–8.CrossRefPubMedPubMedCentral Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000;44:2100–8.CrossRefPubMedPubMedCentral
6.
go back to reference Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;356:297–302.CrossRefPubMed Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;356:297–302.CrossRefPubMed
7.
go back to reference Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998;321:689–97.CrossRefPubMed Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998;321:689–97.CrossRefPubMed
8.
go back to reference Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982–91.CrossRefPubMedPubMedCentral Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982–91.CrossRefPubMedPubMedCentral
9.
go back to reference Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Felix J, Sanhangala E, Andrade BN, Dos Santos Souza S, Talundzic E, et al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.CrossRefPubMedPubMedCentral Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Felix J, Sanhangala E, Andrade BN, Dos Santos Souza S, Talundzic E, et al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.CrossRefPubMedPubMedCentral
10.
go back to reference Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, Quang HH, Farrar J, Thwaites G, White NJ, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRefPubMedPubMedCentral Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, Quang HH, Farrar J, Thwaites G, White NJ, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J. 2017;16:27.CrossRefPubMedPubMedCentral
11.
go back to reference Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedPubMedCentral Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRefPubMedPubMedCentral
13.
go back to reference Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C, Woodrow CJ, Ashley EA, et al. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9:1769.CrossRefPubMedPubMedCentral Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C, Woodrow CJ, Ashley EA, et al. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nat Commun. 2018;9:1769.CrossRefPubMedPubMedCentral
17.
go back to reference Klein EY. Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents. 2013;41:311–7.CrossRefPubMedPubMedCentral Klein EY. Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents. 2013;41:311–7.CrossRefPubMedPubMedCentral
18.
20.
go back to reference WHO. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1973;529:1–121. WHO. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1973;529:1–121.
21.
go back to reference Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol. 2003;206:3745–52.CrossRefPubMed Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol. 2003;206:3745–52.CrossRefPubMed
22.
go back to reference Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:75.CrossRefPubMedPubMedCentral Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:75.CrossRefPubMedPubMedCentral
23.
go back to reference Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Martensson A, Rosenthal PJ, Dorsey G, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.CrossRefPubMedPubMedCentral Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Martensson A, Rosenthal PJ, Dorsey G, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.CrossRefPubMedPubMedCentral
24.
go back to reference Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J. 2009;8:89.CrossRefPubMedPubMedCentral Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J. 2009;8:89.CrossRefPubMedPubMedCentral
25.
go back to reference Nsanzabana C, Ariey F, Beck HP, Ding XC, Kamau E, Krishna S, Legrand E, Lucchi N, Miotto O, Nag S, et al. Molecular assays for antimalarial drug resistance surveillance: a target product profile. PLoS One. 2018;13:e0204347.CrossRefPubMedPubMedCentral Nsanzabana C, Ariey F, Beck HP, Ding XC, Kamau E, Krishna S, Legrand E, Lucchi N, Miotto O, Nag S, et al. Molecular assays for antimalarial drug resistance surveillance: a target product profile. PLoS One. 2018;13:e0204347.CrossRefPubMedPubMedCentral
26.
go back to reference Sarmah NP, Sarma K, Bhattacharyya DR, Sultan AA, Bansal D, Singh N, Bharti PK, Sehgal R, Mohapatra PK, Parida P, Mahanta J. Antifolate drug resistance: novel mutations and haplotype distribution in dhps and dhfr from Northeast India. J Biosci. 2017;42:531–5.CrossRefPubMed Sarmah NP, Sarma K, Bhattacharyya DR, Sultan AA, Bansal D, Singh N, Bharti PK, Sehgal R, Mohapatra PK, Parida P, Mahanta J. Antifolate drug resistance: novel mutations and haplotype distribution in dhps and dhfr from Northeast India. J Biosci. 2017;42:531–5.CrossRefPubMed
27.
go back to reference Mishra S, Bharti PK, Shukla MM, Ali NA, Kashyotia SS, Kumar A, Dhariwal AC, Singh N. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014. Pathog Glob Health. 2017;111:186–94.CrossRefPubMedPubMedCentral Mishra S, Bharti PK, Shukla MM, Ali NA, Kashyotia SS, Kumar A, Dhariwal AC, Singh N. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014. Pathog Glob Health. 2017;111:186–94.CrossRefPubMedPubMedCentral
28.
go back to reference Burrow R: Sensitivity and specificity of molecular methods for detecting markers of antimalarial drug resistance in clinical samples of Plasmodium falciparum: a systematic review. In Department of Continuing Education: University of Oxford; 2017. Burrow R: Sensitivity and specificity of molecular methods for detecting markers of antimalarial drug resistance in clinical samples of Plasmodium falciparum: a systematic review. In Department of Continuing Education: University of Oxford; 2017.
29.
go back to reference McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the P-DTAG, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96.CrossRefPubMed McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the P-DTAG, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96.CrossRefPubMed
30.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRefPubMedPubMedCentral Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRefPubMedPubMedCentral
31.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
32.
go back to reference Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, Gotzsche PC, Lasserson T, Tovey D, Group PfA. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10:e1001419.CrossRefPubMedPubMedCentral Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, Gotzsche PC, Lasserson T, Tovey D, Group PfA. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10:e1001419.CrossRefPubMedPubMedCentral
33.
go back to reference Handbook for diagnostic test accuracy reviews. Handbook for diagnostic test accuracy reviews.
34.
go back to reference CRD. Systematic reviews: CRD’s guidance for undertaking reviews in health care. [3rd ed]. York: Centre for Reviews and Dissemination; 2009. CRD. Systematic reviews: CRD’s guidance for undertaking reviews in health care. [3rd ed]. York: Centre for Reviews and Dissemination; 2009.
35.
go back to reference Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Oxford: Wiley-Blackwell; 2008.CrossRef Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Oxford: Wiley-Blackwell; 2008.CrossRef
36.
go back to reference Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMed Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMed
37.
go back to reference Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.CrossRefPubMedPubMedCentral Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.CrossRefPubMedPubMedCentral
39.
go back to reference Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93.CrossRefPubMed Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93.CrossRefPubMed
40.
go back to reference Schunemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, Scholten R, Langendam M, Leeflang MM, Akl EA, et al. GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89–98.CrossRefPubMed Schunemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, Scholten R, Langendam M, Leeflang MM, Akl EA, et al. GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89–98.CrossRefPubMed
Metadata
Title
Diagnostic accuracy of molecular methods for detecting markers of antimalarial drug resistance in clinical samples of Plasmodium falciparum: protocol for an update to a systematic review and meta-analysis
Authors
Rebekah Burrow
Thomas R. Fanshawe
Georgina S. Humphreys
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2018
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-018-0891-6

Other articles of this Issue 1/2018

Systematic Reviews 1/2018 Go to the issue